Analysts expect that BioCardia, Inc. (NASDAQ:BCDA) will post $50,000.00 in sales for the current quarter, according to Zacks. Two analysts have provided estimates for BioCardia’s earnings, with the lowest sales estimate coming in at $40,000.00 and the highest estimate coming in at $60,000.00. BioCardia also reported sales of $50,000.00 in the same quarter last year. The company is scheduled to issue its next quarterly earnings results on Tuesday, March 29th.
According to Zacks, analysts expect that BioCardia will report full year sales of $580,000.00 for the current financial year, with estimates ranging from $150,000.00 to $1.00 million. For the next year, analysts forecast that the business will post sales of $500,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow BioCardia.
BioCardia (NASDAQ:BCDA) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. BioCardia had a negative return on equity of 72.74% and a negative net margin of 1,237.37%. The company had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.04 million. During the same period in the prior year, the company posted ($0.30) EPS.
NASDAQ BCDA traded down $0.15 during trading hours on Tuesday, reaching $1.72. 500 shares of the company’s stock were exchanged, compared to its average volume of 348,529. BioCardia has a one year low of $1.65 and a one year high of $5.48. The firm has a fifty day moving average of $2.11 and a 200-day moving average of $2.88.
A number of hedge funds have recently modified their holdings of BCDA. CM Management LLC raised its position in shares of BioCardia by 5.1% in the second quarter. CM Management LLC now owns 329,000 shares of the company’s stock valued at $1,306,000 after buying an additional 15,900 shares in the last quarter. Vanguard Group Inc. increased its stake in BioCardia by 67.8% in the second quarter. Vanguard Group Inc. now owns 411,969 shares of the company’s stock valued at $1,636,000 after acquiring an additional 166,396 shares during the last quarter. Geode Capital Management LLC increased its stake in BioCardia by 23.6% in the second quarter. Geode Capital Management LLC now owns 76,825 shares of the company’s stock valued at $304,000 after acquiring an additional 14,657 shares during the last quarter. Virtu Financial LLC bought a new position in BioCardia in the second quarter valued at approximately $132,000. Finally, Commonwealth Equity Services LLC bought a new position in BioCardia in the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 17.00% of the company’s stock.
BioCardia, Inc operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs.
Read More: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.